Related references
Note: Only part of the references are listed.Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+and CD4+T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
Souvik Dey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
I-M. Svane et al.
ANNALS OF ONCOLOGY (2020)
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
Nicolai Gronne Jorgensen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines
Ketty Peris et al.
EUROPEAN JOURNAL OF CANCER (2019)
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
Aaron M. Goodman et al.
ONCOIMMUNOLOGY (2018)
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response
Morten Orebo Holmstroem et al.
ONCOIMMUNOLOGY (2018)
Anti-programmed cell death-1 therapy in nonmelanoma skin cancer
J. K. Winkler et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities
Julia Chang et al.
JAMA DERMATOLOGY (2017)
The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older A Systematic Review
Satish F. K. Lubeek et al.
JAMA DERMATOLOGY (2017)
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
Sadakatsu Ikeda et al.
NPJ GENOMIC MEDICINE (2016)
Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
Stephane Ascarateil et al.
Journal for ImmunoTherapy of Cancer (2015)
Mutational Landscape of Basal Cell Carcinomas by Whole-Exome Sequencing
Shyam S. Jayaraman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
S. M. Ahmad et al.
LEUKEMIA (2014)
Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
Brigitte Dreno et al.
ONCOLOGIST (2014)
HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
Shamaila Munir et al.
CANCER RESEARCH (2013)
Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
S. Munir et al.
LEUKEMIA (2013)
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells
Shamaila Munir et al.
ONCOIMMUNOLOGY (2013)
A systematic review of worldwide incidence of nonmelanoma skin cancer
A. Lomas et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma
Erik H. J. G. Aarntzen et al.
CANCER RESEARCH (2012)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Basal Cell Carcinoma with Spontaneous Regression: A Case Report and Immunohistochemical Study
Taku Fujimura et al.
CASE REPORTS IN DERMATOLOGY (2012)
Basal cell carcinoma: analysis of regression after incomplete excision
V. Zemelman et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
IJM de Vries et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nonmelanoma skin cancer in organ transplant patients
GBE Jemec et al.
TRANSPLANTATION (2003)
Cytokine profiles in spontaneously regressing basal cell carcinomas
DA Wong et al.
BRITISH JOURNAL OF DERMATOLOGY (2000)
Share Paper
